Recent News

• 11.04.2026 - Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives
• 11.02.2026 - Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
• 10.22.2026 - Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
• 10.20.2026 - Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
• 10.15.2026 - Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026
• 10.08.2026 - Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
• 09.16.2026 - Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
• 08.27.2026 - Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
• 08.25.2026 - Beyond Eligibility: The Real Impact of the 2026 NCCN Genetic Testing Updates
• 07.30.2026 - Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

Recent Filings

• 10.27.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.20.2026 - 8-K Current report
• 10.20.2026 - EX-99.1 EX-99.1
• 10.09.2026 - 8-K Current report
• 09.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.17.2026 - 3 Initial statement of beneficial ownership of securities
• 09.16.2026 - 8-K Current report
• 09.16.2026 - EX-99.1 EX-99.1